Brexin 20

Quick links to important sections

Brexin 20

Treatment option:

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brexin 20

Property Description
Active ingredient Piroxicam
Form Tablet, Powder for oral solution
Pharmacological class Non-steroidal Anti-inflammatory Drug (NSAID)
Common purpose Symptomatic relief of pain and inflammation
Origin Synthetic compound

What Type of Medicine is Brexin 20?

Brexin 20 is a proprietary pharmaceutical preparation classified as a Non-steroidal Anti-inflammatory Drug (NSAID), with the synthetic active ingredient Piroxicam, delivered via oral administration. Piroxicam belongs specifically to the oxicam family and is primarily known as a potent inhibitor of cyclooxygenase enzymes, which underlies its therapeutic function. The classification confirms the drug's fundamental purpose is to modulate inflammatory and pain responses to provide overall symptomatic relief. Piroxicam exhibits a distinctively long half-life in the body, which supports a prolonged duration of action compared to many standard NSAIDs.

Brexin 20 Composition and Available Forms

The key differentiating feature of Brexin 20's composition is the unique complex known as Piroxicam-β-cyclodextrin. This formulation involves chemically binding the active Piroxicam molecule to Beta-cyclodextrin, an inert, molecular carrier. This specific complexation method dramatically improves the drug's solubility and overall bioavailability and absorption rate compared to traditional, uncomplexed Piroxicam. This single active substance product is designed for oral administration and is supplied in two main oral dosage forms: the scored tablet and the powder for oral solution.

What is the General Purpose of Brexin 20?

The general purpose of Brexin 20 is to deliver comprehensive symptomatic relief through its inherent triple physiological action: it is analgesic (eases pain), anti-inflammatory (reduces swelling), and antipyretic (helps reduce fever). By blocking the synthesis of prostaglandins, the medicine directly addresses the biochemical sources of these discomforts. Its ultimate purpose is the modulation of inflammatory responses and the reduction of associated core symptoms, such as stiffness and general musculoskeletal discomfort, with the rapid absorption enabled by its unique formulation providing a faster onset of its analgesic action.

What side effects are possible with Brexin 20?

Possible Side Effects and Safety Information

Brexin 20 (Piroxicam) is a Non-steroidal Anti-inflammatory Drug (NSAID), and its safety profile is defined by officially documented risks common to this class, as outlined in regulatory documents.

Serious Adverse Reactions

Regulatory warnings highlight the potential for two principal classes of serious adverse reactions, which can occur without warning symptoms. The first is an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke. This risk may increase with the duration of use. The second involves serious gastrointestinal adverse events, including bleeding, ulceration, and perforation of the stomach or intestines. Rarely, Severe Cutaneous Adverse Reactions (SCARs), such as Stevens-Johnson Syndrome (SJS), have been reported, with the highest risk noted during the initial weeks of treatment.

Common and Organ System-Related Effects

Adverse reactions are classified by frequency and the body system affected, according to regulatory standards.

Classification System-Organ Class (SOC) Examples of Effects
Common Gastrointestinal Disorders Nausea, Abdominal pain, Indigestion (dyspepsia), Constipation, Diarrhea.
Nervous System Disorders Headache, Dizziness, Vertigo.
General Disorders Peripheral edema (fluid retention).

Less frequent effects have been reported across various systems, including the Blood and Lymphatic system (e.g., anemia), Hepatobiliary system (e.g., jaundice), and Renal system (e.g., renal failure).

Population-Specific Safety Considerations

Specific safety considerations are documented for certain populations. Older adults are at a greater risk for serious gastrointestinal adverse events. Caution is also required for patients with pre-existing heart failure or hypertension due to the potential for fluid retention. Furthermore, the official label notes that the use of Piroxicam may cause a reversible impairment of female fertility.

Overdose and Emergency Response

Overdose and when to seek help

This section describes official information documented by government regulatory bodies regarding an overdosage of Brexin 20 (Piroxicam).

Documented Overdose Presentations

Overdose manifestations are primarily associated with the drug's effect on the central nervous system, gastrointestinal tract, and renal system. Documented signs and symptoms following an overdose may include nausea, vomiting, stomach pain, diarrhea, headache, and drowsiness. More severe manifestations can involve severe agitation or confusion, blurred vision, ringing in the ears, or unsteadiness.

Serious Outcomes

Immediate medical attention is necessary because very large overdoses carry the risk of serious, life-threatening outcomes. These may include profound low blood pressure (shock), seizures (convulsions), coma, and acute kidney injury (indicated by little to no urine production). Gastrointestinal complications can involve bleeding in the stomach and intestines.

Emergency Response

An overdose occurs when more than the prescribed amount of this medicine is taken. If you suspect an overdose, you must immediately call your local emergency number or a poison control center for guidance.

Summary

Regulatory information defines the overdose profile by listing specific symptoms and high-risk outcomes to underscore the necessity for seeking prompt emergency medical assistance. Do not delay calling for help, even if detailed information is not immediately available.

Therapeutic Uses of Brexin 20

What Brexin 20 Treats: Main Uses and Benefits

The primary role of Brexin 20 is to provide symptomatic relief across therapeutic domains where pain and inflammation cause significant discomfort, supporting patients through both persistent and sudden, acute episodes. The medication is relevant in clinical settings for managing the key symptoms of musculoskeletal conditions.

It is commonly used across conditions presenting with episodic or fluctuating manifestations, including Osteoarthritis, Rheumatoid Arthritis, Ankylosing Spondylitis, and acute gouty arthritis. It is also applied in scenarios requiring short-term symptomatic assistance for conditions like tendinitis, bursitis, and pain from post-traumatic or post-operative events, as well as specific manifestations such as primary dysmenorrhea.

“It offers symptomatic relief that may help patients cope more steadily with difficult, often sudden, episodic manifestations.”

The therapeutic benefit is to help ease the overall symptom burden, contributing to improved day-to-day comfort and assisting with maintaining functional stability.


Quick Fact: Relief for Pain, Swelling, and Stiffness

Symptomatic Support for Chronic and Acute Discomfort

This supportive use helps address symptom clusters that may become intense or disruptive, such as chronic pain, joint tenderness, and noticeable stiffness in long-term joint conditions. It is also applied during phases of increased distress or discomfort associated with acute musculoskeletal flares, offering symptomatic relief when symptoms interfere with routine activities.

Regulatory References

  1. NIH MedlinePlus Drug Information on Piroxicam

Eligibility and Restrictions for Use

Who Can and Cannot Use Brexin 20?

The eligibility profile for Brexin 20 (Piroxicam) is defined by official regulatory rules that establish strict limitations for its use. This medicine is primarily intended for adults who do not possess any absolute contraindications.

Category Official Eligibility Status
Absolute Contraindications Use is prohibited for patients with known hypersensitivity to Piroxicam or other NSAIDs (e.g., aspirin-sensitive asthma), active gastrointestinal ulceration or bleeding, severe uncontrolled heart failure, or a history of cerebrovascular bleeding. It is also contraindicated for pain surrounding Coronary Artery Bypass Graft (CABG) surgery and for concomitant use with other NSAIDs or anticoagulants.
Age and Lifecycle Rules Brexin 20 is contraindicated in children and adolescents under 18 years of age. Use is contraindicated during the third trimester of pregnancy (after 30 weeks gestation) and not recommended during breastfeeding. Administration to patients older than 80 years should be avoided.
Conditional Restrictions Patients with severe hepatic or renal impairment are non-eligible. Patients with pre-existing, non-severe heart failure or cardiovascular disease, as well as those with mild-to-moderate organ impairment, must use the medicine under specific monitoring and caution.

What should I know about interactions with other medicines?

The official regulatory profile for Brexin 20 (Piroxicam) establishes interaction patterns based on the potential for increased pharmacodynamic risk and altered drug exposure.

Contraindicated and Restricted Combinations

Formal restrictions exist for combining Brexin 20 with other Non-steroidal Anti-inflammatory Drugs (NSAIDs), including COX-2 selective agents, and Acetylsalicylic acid at analgesic doses due to a documented additive risk of severe gastrointestinal (GI) events. Co-administration with anticoagulants (e.g., Warfarin) is similarly restricted due to the enhanced risk of hemorrhage. The medication is also contraindicated in the setting of Coronary Artery Bypass Graft (CABG) surgery.

Clinically Significant Pharmacodynamic Interactions

Co-administration with Oral Corticosteroids, SSRIs, and certain anti-platelet agents increases the documented risk of GI ulceration or bleeding. Piroxicam may diminish the therapeutic effect of Diuretics and ACE Inhibitors/ARBs, with a documented risk of renal function deterioration that is accentuated in elderly patients or those with compromised renal function.

Pharmacokinetic and Substance Interactions

Piroxicam has been documented to increase the plasma levels of certain co-administered medicines, including Methotrexate and Digoxin, by reducing their elimination. Piroxicam's elimination is mediated by CYP2C9 hepatic metabolism, and individuals identified as poor metabolizers may experience high systemic exposure. The ingestion of alcohol is officially documented to increase the risk of stomach bleeding associated with Piroxicam. Food intake delays the medicine's absorption but does not alter its total bioavailability.

Mechanism of Action

How Brexin 20 Works

Brexin 20 contains Piroxicam, which exerts its pharmacodynamic action as a non-selective inhibitor of the Cyclooxygenase (COX) enzymes, targeting both COX-1 and COX-2 isoforms. This mechanistic domain is defined by the inhibition halting the chemical cascade that converts arachidonic acid into prostaglandins, which are key signaling molecules involved in localized physiological responses. The resulting reduction in the production of these specific signaling molecules influences the dynamics within the affected eicosanoid signaling pathway.

This altered signaling results in a systemic reduction of pathway activity and decreased stimulation of nociceptors (sensory nerve endings). This action results in decreased downstream effects of the eicosanoid pathway, leading to a reduction in localized vascular changes. Furthermore, the mechanism that reduces levels of these eicosanoid mediators also influences the physiological process of thermoregulation in the brain, modulating activity within the pathways responsible for controlling the body's internal temperature and subsequently lowering the thermoregulatory set point in the hypothalamus.

Dosage and Administration Information

Official Administration Guidelines for Brexin 20

Brexin 20, which contains the active ingredient Piroxicam as a beta-cyclodextrin complex, is approved solely for oral administration. The product is supplied as a 20 mg scored tablet and a 20 mg powder for oral solution.


The use of Brexin 20 is governed by requirements that emphasize conservative dosing and treatment duration, which must be initiated by physicians experienced in treating inflammatory rheumatic diseases.

Usage Parameter Official Regulatory Instruction
Route and Frequency Taken orally, typically once daily as a single dose.
Standard Daily Dose The maximum recommended daily dose is 20 mg Piroxicam equivalent. The usual starting and maintenance dose for chronic conditions is 20 mg daily, though some patients may be maintained on a lower 10 mg daily dose.
Timing and Preparation The dose should be taken preferably with or immediately after food to aid proper administration. The powder for oral solution must be dissolved in liquid before ingestion.
Treatment Duration The overall course of treatment must utilize the minimum effective dose for the shortest duration necessary. The benefit and tolerability of the medicine must be formally reviewed within 14 days of starting therapy.
Older Adults For older adults, special caution and supervision are required; use of the lowest effective dose for the shortest duration is mandated. Dosage recommendations for children are not established.

Procedural Summary

The official protocol for using Brexin 20 establishes a standardized once-daily oral regimen not to exceed 20 mg. This regimen is supported by Piroxicam's long half-life, which enables steady levels with a single daily dose. The requirement to take the medicine with or after food is a key administration condition, and the overall protocol is structured by the mandatory clinical review within 14 days to assess the need for continued treatment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brexin 20

Evidence for Use in Chronic Rheumatic Conditions

Research for Brexin 20 (Piroxicam-β-cyclodextrin), or the underlying Piroxicam compound, was studied for symptoms related to Osteoarthritis, Rheumatoid Arthritis, and Ankylosing Spondylitis. The evidence base for these long-term conditions primarily relies on short- to intermediate-term Randomized Controlled Trials (RCTs) and meta-analyses that evaluated the drug against a placebo or other active treatments.

Research examined patient-reported outcomes, including changes in physical discomfort (pain scores, joint tenderness, and stiffness) and outcomes reflecting daily functioning. However, the follow-up periods were short in many core efficacy trials. Comprehensive data on extended changes in symptoms from dedicated RCTs remain insufficient to fully characterize the long-term effects on function.


Evidence for Use in Acute Pain and Musculoskeletal Flares

Research explored the complexed formulation of Brexin 20 in conditions associated with acute or disruptive episodes, such as post-operative pain, acute gouty arthritis, or short-term flares of tendinitis. These trials often included studies focusing on episodes where symptoms become more noticeable.

Research examined outcomes describing episodic or acute changes, primarily monitoring the time required to report initial changes in symptoms and the consumption of rescue analgesic medication. This evidence contributes to the research base on short-term analgesic responses, but offers limited information for long-term outcomes regarding the prevention of symptom recurrence.


Long-Term Studies and Areas of Uncertainty

When considering long-term outcomes related to systemic or functional imbalance, the evidence typically derives from long-term observational settings for the Piroxicam class as a whole, rather than the short-term efficacy trials of Brexin 20 itself. Definitive, head-to-head evidence from long-term controlled clinical trials comparing the sustained effects against other options is generally lacking.

Research on special populations (e.g., older adults) has been conducted, but data for certain groups remain insufficient, meaning that results apply only to the populations studied. A key limitation is that there is insufficient data from efficacy trials to fully exclude the class-wide associated regulatory concern regarding the potential for arterial thrombotic events. Further research is ongoing to address these uncertainties.

Frequently Asked Questions (FAQ)

Common questions about Brexin 20 (FAQ)


Q: What does 'NSAID' mean in relation to Brexin 20?

Brexin 20 is classified as an NSAID, which stands for Non-Steroidal Anti-Inflammatory Drug. This designation means it is a type of medicine used to relieve discomfort, reduce fever, and decrease swelling without containing steroids.


Q: Do you need a prescription for Brexin 20?

Yes, according to official regulatory status in many regions, Brexin 20 (Piroxicam) is generally classified as a Prescription-Only Medicine. Official guidelines describe that its use is initiated and overseen by a healthcare professional.


Q: Is Brexin 20 considered a first-line treatment for its primary uses?

Regulatory warnings state that Piroxicam, the active component of Brexin 20, is not typically recommended as a first-line treatment for acute conditions, such as sudden pain flares. This is due to safety considerations, specifically concerning the gastrointestinal profile of the drug.


Q: Can Brexin 20 be taken for general aches and pains?

Official product information indicates that Brexin 20 is approved for the symptomatic relief of signs and discomfort related to specific chronic inflammatory conditions, such as rheumatoid arthritis and osteoarthritis. It is not generally indicated for use against minor, general aches and pains.


Q: How quickly does Brexin 20 start to work?

Studies on the absorption rate indicate that the concentration of the medicine in the blood typically peaks within three to five hours after administration. However, official guidance states that the full therapeutic benefit for chronic conditions should not be assessed for two weeks.


Q: How does Brexin 20 differ from ibuprofen?

Brexin 20 contains Piroxicam, which is an oxicam-class NSAID recognized for its long half-life of around 50 hours, allowing it to be taken once daily. Ibuprofen, in contrast, belongs to the propionic acid class of NSAIDs and has a much shorter duration of action.


Q: Is Brexin 20 a strong painkiller?

Brexin 20 is classified as an NSAID possessing analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. The official literature does not use subjective terms like 'strong,' but rather focuses on its documented ability to manage specific inflammatory conditions.


Q: Do studies support the use of Brexin 20 for back pain?

While not a primary indication, the research base for the Piroxicam component includes clinical trials that have explored its use for conditions like acute low-back pain. Evidence suggests short-term pain relief in such episodes, consistent with the specific professional guidance required for this medicine.


Q: Is there a generic version of Brexin 20 available?

Brexin 20 is the brand name for the Piroxicam-beta-cyclodextrin formulation. Although this specific complex is proprietary, the active ingredient, Piroxicam, is widely available in generic tablet and capsule forms from various manufacturers.


Q: Is it safe to use Brexin 20 with antacids?

Studies have shown that concomitant use of antacids typically has no significant effect on the levels of Piroxicam in the bloodstream. The official label information advises informing a prescribing doctor of all medicines being taken.


Q: Can Brexin 20 interact with herbal supplements?

Official patient information often contains a general warning advising individuals to inform their healthcare provider about all herbal and traditional products they are taking. This disclosure is a general practice to help ensure comprehensive understanding of potential substance interactions.


Q: Does Brexin 20 contain penicillin or sulfa?

The active ingredient, Piroxicam, belongs to the oxicam class of NSAIDs and is structurally unrelated to both penicillin and sulfa derivatives. The full list of non-medicinal ingredients is detailed on the official product label.


Q: Is Brexin 20 considered a controlled substance?

No, regulatory bodies do not classify Brexin 20 (Piroxicam) as a controlled substance. It is an NSAID and is not listed in any government-controlled substance scheduling.


Q: Does Brexin 20 cause drowsiness?

Drowsiness, dizziness, or unusual tiredness are listed in the product information as a possible adverse effect. Official guidance notes that if these effects occur, activities requiring mental alertness, such as driving or operating machinery, should be approached with caution.


Q: Is it normal to feel a change in appetite while taking Brexin 20?

Loss of appetite, also known as anorexia, has been listed in the reported adverse events for the Piroxicam component. Official guidelines typically advise that any significant change in appetite should be brought to the attention of a healthcare provider.


Q: What happens if I miss a dose of Brexin 20?

If a dose is forgotten, official patient information advises to skip the missed dose and take the next dose at its usual scheduled time. Official patient information explicitly states that taking a double dose to compensate for the forgotten dose is not advised.


Q: Is the Brexin 20 tablet meant to be swallowed whole?

The Brexin 20 tablet has a score line, and regulatory patient information indicates that the score is present to ease splitting the tablet, which may help with swallowing. It can generally be taken with a glass of water.


Q: Are there known cases of Brexin 20 causing skin rashes?

Yes, skin rashes and hypersensitivity reactions have been reported. Regulatory warnings state that if a skin rash appears, the medicine is typically discontinued due to the rare, but serious, risk of severe cutaneous adverse reactions (SCARs).


Q: Are allergic reactions common with Brexin 20?

Allergic reactions and hypersensitivity are known risks, and severe forms like Stevens-Johnson Syndrome (SCARs) are reported, though rare. However, official information does not provide a general frequency classification (common or uncommon) for all non-severe allergic reactions.

How should Brexin 20 be stored and disposed of?

How to Store and Dispose of Brexin 20?

Brexin 20 storage and disposal must strictly adhere to regulatory guidelines to maintain product stability and ensure environmental safety.

Official Storage Requirements

Condition Regulatory Requirement
Temperature Store below 30 C.
Protection Must be protected from sunlight and moisture.
Handling Do not refrigerate or freeze.
Child Safety Keep out of the sight and reach of children.

Disposal Instructions

Unused or expired Brexin 20 must be disposed of in accordance with local regulations or a medicine take-back program. It is prohibited to discard the medicine by flushing it down the toilet or pouring it down the sink, as this prevents the active ingredient from entering the sewage system and environment.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Equivalent of Brexin 20 found in:

A-Z Index: